Window of Opportunity Trial of Neoadjuvant ADXS11-001 Vaccination prior to Robot-Assisted Resection of HPV-Positive Oropharyngeal Squamous Cell Carcinoma

ID Number 13-1411

Principal Investigator(s)
Andrew Sikora

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to determine the immunogenicity of ADX11-001 vaccination in patients with HPV+ squamous cell carcinoma of the oropharynx. Also, to evaluate the tolerability, safety, and nature and degree of toxicity of ADX11-001 by the numbers of patients with dose limiting toxicities (DLTs) and adverse events as assessed by the CTCAE v4.0

Contact Information
(212) 824-7309

Recruiting Patients: Yes